The efficacy of intradermal polydioxanone injection in treating atrophic acne scar : A randomized, split-face, pilot study

The Efficacy of Intradermal Polydioxanone Injection in Treating Atrophic Acne Scar : A Randomized, Split-Face, Pilot Study

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250319002

Enrollment

Registered

2025-03-19

Start date

2025-01-28

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic acne scar Atrophic acne scar

Interventions

Polydioxanone (PDO) is biostimulator ( a substance induces collagen production, promoting regeneration of collagen within the skin) Prepare the study substance, Powdered polydioxanone 100 mg/vial (Ul

Experimental Drug,Placebo Comparator Drug

polydioxanone (Ultracol100),sterile water

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. individuals with atrophic acne scar at both cheeks 2. age 20 to 50

Exclusion criteria

Exclusion criteria: 1. individuals with active acne at cheek 2. allergy to polydioxanone or anesthetic drug 3. individuals undergoing atrophic acne scar therapy/received facial aesthetic treatment within the past 6 months 4. chronic medical condition 5. inflammatory skin disease 6. vitamin A and derivative/steroid use 7. smoking 8. pregnancy or breast feeding

Design outcomes

Primary

Measure	Time frame
volume & size of atrophic acne scar 0,1,2,3 months visioscan & vernier caliper	—

Secondary

Measure	Time frame
side effect & pain score & satisfaction 0,1,2,3 months GAIS	—

Countries

Thailand

Contacts

Public ContactAcharavadee Mahatnirunkul

Dhurakij Pundit University

peppermintttt@gmail.com0865082514

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026